<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00412542</url>
  </required_header>
  <id_info>
    <org_study_id>DM02-595</org_study_id>
    <nct_id>NCT00412542</nct_id>
  </id_info>
  <brief_title>Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas</brief_title>
  <official_title>A Phase II Trial of Combination Therapy With Thalidomide and CPT-11 in Patients With Recurrent Anaplastic Gliomas or Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives:

      1.1 To determine the efficacy, as measured by 6 month progression-free survival, of therapy
      with thalidomide combined with CPT-11 in the treatment of patients with recurrent and/or
      progressive malignant gliomas.

      1.2 To determine the rate of measureable clinical response in patients treated with
      Thalidomide and CPT-11.

      1.3 To determine Thrombotic thrombocytopenic purpura (TTP), overall survival and unexpected
      toxicity of Thalidomide and CPT-11 used in recurrent malignant gliomas.

      1.4 To determine changes in dynamic magnetic resonance imaging (MRI) as a surrogate marker
      for treatment effect.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thalidomide is a drug that interferes with the growth of blood vessels. Thalidomide may help
      to decrease the blood supply in the tumor and make it unable to grow. CPT-11 is a drug that
      was designed to stop cancer cells from dividing.

      All participants will take thalidomide capsules by mouth every evening at bedtime. You will
      begin with 1 capsule every night for the first week then increase to 2 capsules every night
      for a week and then 3 capsules a night for the third week. After that, you will increase the
      dose to 4 capsules each night for the rest of the study. The dosages may be adjusted if you
      experience any severe side effects.

      In addition to thalidomide, you will receive treatment with CPT-11 through a continuous
      injection into a vein over 90 minutes once a week for 4 weeks followed by 2 weeks of rest
      from the drug. This 6 week period is called a course of therapy. The courses of therapy will
      be repeated as long as the disease is responding to treatment for up to 2 years.

      THIS IS AN INVESTIGATIONAL STUDY. Both drugs are commercially available. Thalidomide and
      CPT-11 are FDA approved for the treatment of some cancers. The combination of these drugs is
      investigational.

      Up to 78 participants will take part in this study. All will be enrolled at M. D. Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Progression Free at 6 Months With Malignant Gliomas</measure>
    <time_frame>6 Months</time_frame>
    <description>Progression-free Survival (PFS) measured as number of participants that are alive and progression-free at 6 months.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">78</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <condition>Glioma</condition>
  <arm_group>
    <arm_group_label>Thalidomide + CPT-11</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Thalidomide 100 mg daily for 8 weeks + CPT-11 125 mg/m^2 by vein weekly over 90 minutes for 4 weeks, followed by 2 weeks rest.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thalidomide</intervention_name>
    <description>100 mg PO (by mouth) daily for 8 weeks</description>
    <arm_group_label>Thalidomide + CPT-11</arm_group_label>
    <other_name>Thalomid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPT-11</intervention_name>
    <description>125 mg/m^2 by vein weekly over 90 minutes for 4 weeks, followed by 2 weeks rest</description>
    <arm_group_label>Thalidomide + CPT-11</arm_group_label>
    <other_name>Irinotecan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRI Scan</intervention_name>
    <description>Dynamic MRI scan with dye injection through vein, every 6 weeks</description>
    <arm_group_label>Thalidomide + CPT-11</arm_group_label>
    <other_name>Magnetic Resonance Imaging</other_name>
    <other_name>MR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Quantitative Sensory Tests (QST)</intervention_name>
    <description>QST, every 12 weeks, to check for any nerve problems that may be present before starting treatment; by touching a small machine tests are done on feeling of touch, vibration, and temperature.</description>
    <arm_group_label>Thalidomide + CPT-11</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Is there an age limit? No

        Inclusion Criteria:

          1. Patients with histologically proven supratentorial malignant primary gliomas
             (Glioblastoma multiforme (GBM), Gliosarcoma (GS) Anaplastic astrocytoma (AA),
             Anaplastic oligodendroglioma (AO), mixed anaplastic glioma (MAG)) will be eligible for
             this protocol.

          2. Patients must have shown unequivocal evidence for tumor recurrence or progression by
             MRI scan after radiation therapy.

          3. Patients in the GBM stratum may have had treatment for no more than 2 prior relapses;
             for the AA stratum, there is no limitation for the number of relapses provided all
             other eligibility criteria particularly the functional status are met.

          4. All patients must sign an informed consent.

          5. The baseline on-study MRI should be performed within 14 days prior to registration and
             on a stable or decreasing steroid dosage.

          6. Patients having undergone recent resection of recurrent or progressive tumor will be
             eligible.

          7. Patients must have a life expectancy &gt; 8 weeks.

          8. Patients must have a Karnofsky performance status of &gt;= 70

          9. Patients must have recovered from the toxic effects of prior therapy: 4 weeks from
             prior cytotoxic therapy and/or at least two weeks from vincristine, 6 weeks from
             nitrosoureas, 3 weeks from procarbazine administration, and 1 week for non-cytotoxic
             agents, e.g., interferon, tamoxifen, cis-retinoic acid, etc. (radiosensitizer does not
             count). Patients who receive either Temozolomide or CPT-11 for non-therapeutic
             purposes (such as presurgically for obtaining pharmacology data for the agent) will be
             eligible for study entry provided they have recovered from the toxic effects of the
             agent if any.

         10. Patients must have adequate bone marrow function (Absolute neutrophil count (ANC)&gt;
             1,500/mm3 and platelet count of &gt; 100,000/mm3), adequate liver function (alanine
             aminotransferase (ALT or SGPT) and alkaline phosphatase &lt;2 times normal, bilirubin
             &lt;1.5 mg/dl), and adequate renal function (blood urea nitrogen (BUN) and creatinine
             &lt;1.5 times institutional normal) prior to starting therapy.

         11. Patients must not be pregnant and must practice adequate contraception during the
             study and for 2 months after participation in study.

        Exclusion Criteria:

          1. Patients with a history of any other cancer (except non-melanoma skin cancer or
             carcinoma in-situ of the cervix), unless in complete remission and off of all therapy
             for that disease for a minimum of 3 years are ineligible.

          2. Patients must not have: a) active infection b) disease that will obscure toxicity or
             dangerously alter drug metabolism c) serious intercurrent medical illness. d) prior
             recurrence with CPT-11 (for the CPT-11 + Thalidomide arm) (prior treatment with
             thalidomide is permitted). e) grade 2 or higher peripheral neuropathy. Patients who
             have received Temozolomide or CPT-11 for non-therapeutic purposes (for eg., as part of
             a pharmacology study without therapeutic intent) will remain eligible for enrollment
             into the study.

          3. No exclusion to this study will be based on race. Minorities will actively be
             recruited to participate. The malignant glioma patient population treated at MDACC
             over the past year is as follows: American Indian or Alaskan Native - 0 Asian or
             Pacific Islander - &lt;2% Black, not of Hispanic Origin - 3% Hispanic - 6% White, not of
             Hispanic Origin - 88% Other or Unknown - 2% Total-100%
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vinay K. Puduvalli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.T.M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>The University of Texas M.D.Anderson Cancer Center</description>
  </link>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 15, 2006</study_first_submitted>
  <study_first_submitted_qc>December 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2006</study_first_posted>
  <results_first_submitted>February 8, 2012</results_first_submitted>
  <results_first_submitted_qc>February 8, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 28, 2012</results_first_posted>
  <last_update_submitted>February 8, 2012</last_update_submitted>
  <last_update_submitted_qc>February 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioblastoma Multiforme</keyword>
  <keyword>Glioma</keyword>
  <keyword>Thalidomide</keyword>
  <keyword>Thalomid</keyword>
  <keyword>CPT-11</keyword>
  <keyword>Irinotecan</keyword>
  <keyword>malignant glioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: October 13, 2003 to October 22, 2008. All participants were recruited at UT MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Of the 78 participants enrolled, three (3) were considered not evaluable.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Glioblastoma Multiforme: Thalidomide + CPT-11</title>
          <description>Oral Thalidomide 100 mg daily for 8 weeks + CPT-11 125 mg/m^2 by vein weekly over 90 minutes for 4 weeks, followed by 2 weeks rest.</description>
        </group>
        <group group_id="P2">
          <title>Anaplastic Gliomas: Thalidomide + CPT-11</title>
          <description>Oral Thalidomide 100 mg daily for 8 weeks + CPT-11 125 mg/m^2 by vein weekly over 90 minutes for 4 weeks, followed by 2 weeks rest.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Eligible</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Glioblastoma Multiforme: Thalidomide + CPT-11</title>
          <description>Oral Thalidomide 100 mg daily for 8 weeks + CPT-11 125 mg/m^2 by vein weekly over 90 minutes for 4 weeks, followed by 2 weeks rest.</description>
        </group>
        <group group_id="B2">
          <title>Anaplastic Gliomas: Thalidomide + CPT-11</title>
          <description>Oral Thalidomide 100 mg daily for 8 weeks + CPT-11 125 mg/m^2 by vein weekly over 90 minutes for 4 weeks, followed by 2 weeks rest.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="33"/>
            <count group_id="B2" value="45"/>
            <count group_id="B3" value="78"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Progression Free at 6 Months With Malignant Gliomas</title>
        <description>Progression-free Survival (PFS) measured as number of participants that are alive and progression-free at 6 months.</description>
        <time_frame>6 Months</time_frame>
        <population>7 participants enrolled were not evaluated as they were evaluable for toxicity only (not having completed the first cycle/clinical decline/etc.).</population>
        <group_list>
          <group group_id="O1">
            <title>Participants With Recurrent Malignant Gliomas</title>
            <description>The endpoints combined results of all strata (Arm 1 of Glioblastoma Multiforme: Thalidomide + CPT-11 and Arm 2 of Anaplastic Gliomas: Thalidomide + CPT-11).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Progression Free at 6 Months With Malignant Gliomas</title>
          <description>Progression-free Survival (PFS) measured as number of participants that are alive and progression-free at 6 months.</description>
          <population>7 participants enrolled were not evaluated as they were evaluable for toxicity only (not having completed the first cycle/clinical decline/etc.).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>4 years and 11 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Patients With Recurrent Malignant Gliomas</title>
          <description>The endpoints combined results of all strata</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Patient was admitted for Grade 2 nausea, possibly related</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>Patient admitted for Grade 2 vomiting, possibly related</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Patient admitted for Grade 2 diarrhea, possibly related</description>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Fecal incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Subdural fluid collection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated ALT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Elevated Creatinine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculo-skeletal leg cramps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>Of the 6 deaths reported, 3 were directly related to disease progression of malignant gliomas. The other 3 were due to complications of other events</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <description>Patient was admitted overnight for Grade 3 seizure, unlikely related</description>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Cerebral edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombus pulmonary embolus</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Thrombus - deep vein thrombosis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="5" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Anemia/decreased hemoglobin</sub_title>
                <counts group_id="E1" events="195" subjects_affected="57" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="315" subjects_affected="65" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="284" subjects_affected="52" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Neutrophils, absolute count</sub_title>
                <counts group_id="E1" events="249" subjects_affected="55" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="52" subjects_affected="25" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Cushingoid</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="19" subjects_affected="12" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal cramping</sub_title>
                <counts group_id="E1" events="18" subjects_affected="9" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="22" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="91" subjects_affected="46" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="171" subjects_affected="46" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="119" subjects_affected="38" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pain, abdominal</sub_title>
                <counts group_id="E1" events="34" subjects_affected="17" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="57" subjects_affected="22" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="42" subjects_affected="31" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="143" subjects_affected="63" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Fever without neutropenia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="18" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="26" subjects_affected="23" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alkaline Phosphatase increased</sub_title>
                <counts group_id="E1" events="18" subjects_affected="11" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>ALT increased</sub_title>
                <counts group_id="E1" events="40" subjects_affected="17" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>AST elevated</sub_title>
                <counts group_id="E1" events="19" subjects_affected="12" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Bicarbonate sodium, low</sub_title>
                <counts group_id="E1" events="30" subjects_affected="16" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Bilirubin elevated</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>BUN elevated</sub_title>
                <counts group_id="E1" events="20" subjects_affected="12" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Cholesterol elevated</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>CPK elevated</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Creatinine elevated</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Elevated chloride</sub_title>
                <counts group_id="E1" events="38" subjects_affected="18" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Elevated CO2</sub_title>
                <counts group_id="E1" events="27" subjects_affected="14" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Elevated AST</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="47" subjects_affected="24" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hypomagnesium</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="34" subjects_affected="19" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="56" subjects_affected="24" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Low protein</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="130" subjects_affected="49" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="53" subjects_affected="23" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="57" subjects_affected="21" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness lower extremity</sub_title>
                <counts group_id="E1" events="36" subjects_affected="25" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Muscle weakness facial</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Muscle weakness left or right sides</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Muscle weakness generalized</sub_title>
                <counts group_id="E1" events="21" subjects_affected="15" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pain, back</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pain, chest (non cardiac)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pain, extremity</sub_title>
                <counts group_id="E1" events="18" subjects_affected="9" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Cognitive disturbance</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="55" subjects_affected="32" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dysphasia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Gait/walking</sub_title>
                <counts group_id="E1" events="37" subjects_affected="31" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Memory Impairment</sub_title>
                <counts group_id="E1" events="29" subjects_affected="26" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Neuropathy motor</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Neuropathy sensory</sub_title>
                <counts group_id="E1" events="52" subjects_affected="35" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pain, headache</sub_title>
                <counts group_id="E1" events="75" subjects_affected="39" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Pyramidal tract dysfunction</sub_title>
                <counts group_id="E1" events="27" subjects_affected="19" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="48" subjects_affected="25" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="25" subjects_affected="20" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Speech impairment</sub_title>
                <counts group_id="E1" events="28" subjects_affected="19" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Tremors</sub_title>
                <counts group_id="E1" events="22" subjects_affected="18" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="22" subjects_affected="16" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Mood alteration</sub_title>
                <counts group_id="E1" events="20" subjects_affected="18" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Incontinence, urinary</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Urinary frequency</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="33" subjects_affected="24" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Nasal/paranasal reactions</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="17" subjects_affected="12" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Bruising (without thrombocytopenia)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vinay Puduvalli, MD / Associate Professor</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>713-745-5769</phone>
      <email>kuhunter@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

